FindTrial
Sign In

TO STUDY USES OF MAGNESIUM PHOSPHORICUM 30 IN SPASMODIC DYSMENORRHOEA

â?? TO STUDY THE EFFICACY OF MAGNESIUM PHOSPHORICUM 30 IN CASES OF SPASMODIC DYSMENORRHOEAâ?? - MPSD30

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048033
Enrollment
120
Registered
2022-12-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

Intervention1: Magnesium Phosphoricum 30: 30 Potency, Orally 4 globules TDS at time of Menses, Every month for a year

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.female 13-21 age group included in my study 2.verbal multi dimensional scale score 1 and 2 included in my study 3.patient willing take treatment regularly and cooperating for follow ups are included in my study

Exclusion criteria

Exclusion criteria: 1.Patientnot fulfilling the case defination of spsmodic dysmenorhhoea 2.patient who requiremergency medical intervention 3.patient without written consent 4.immuno-compromised patients 5.patient not willing take treatment regularly and not cooperating for follow ups 6.verbal multi dimensional scale score3 excluded in my study

Design outcomes

Primary

MeasureTime frame
VERBAL MULTI DIMENSIONAL SCALE SCORE 0Timepoint: 12 MONTHS—

Secondary

MeasureTime frame
Quality of life improvedTimepoint: 12 MONTHS—

Countries

India

Contacts

Public ContactDr Ashwini Kaluram Bhondave

BVDUHMC Katraj,Pune 33

drarunbjadhav@gmail.com9822314520

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026